We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Causes of Bowel Cancer Clarified

By LabMedica International staff writers
Posted on 14 Jul 2016
Colorectal cancer (CRC) displays a complex pattern of inheritance and it is postulated that much of the missing heritability of CRC is enshrined in high-impact rare alleles, which are mechanistically and clinically important.

A landmark study has given the most detailed picture yet of the genetics of bowel cancer, the UK's fourth most common cancer, and the genetic architecture of CRC susceptibility encompasses a broad spectrum of risk, from rare, highly penetrant germline mutations associated with well-characterized syndromes to common polymorphisms, each individually conferring small risk.

Scientists at the Institute of Cancer Research (London, UK) and their colleagues included in a study 1,028 unrelated patients (559 male) with CRC, aged ≤55 years at diagnosis (mean age 48.7 ± 6.0), who had at least one first-degree relative with CRC, ascertained between 2003 and 2011. All the patients were UK residents and had self-reported European ancestry. Germline DNA was isolated from EDTA-venous bloods using standard methods and picogreen quantified. The controls comprised 1,644 healthy individuals from the UK and an additional 670 individuals, all who were sequenced.

A Covaris E Series instrument (Covaris Inc., Woburn, MA, USA) was used to fragment 1 μg of DNA from each individual. Illumina’s Truseq 62 Mb expanded exome enrichment kit was used to prepare indexed paired-end libraries, 2 × 100 bp sequencing was performed using the HiSeq2000 technology (Illumina, San Diego, CA, USA). The scientists also performed read mapping and variant analysis, sample-level quality control, ExomeArray concordance and other methodologies.

The investigators found that added together, all the discovered variants in the known bowel cancer genes accounted for less than a third of familial cases of bowel cancer, those occurring in people whose close relatives had already developed it. The rest of the familial cases must therefore be caused largely by minor DNA variations that in combination add up to increase risk, with environmental factors also contributing. For an individual person, the risk of developing bowel cancer comes from a mix of inherited risk through their genes and environmental risk, which is caused by non-genetic factors such as lifestyle. Around 12% of cases occur in people with a family history of bowel cancer, with inherited mutations in known cancer-causing genes such as Adenomatous Polyposis Coli (APC) and MutL Homolog 1(MLH1) often playing a major role.

Richard S.Houlston, MD, PhD, a Professor of Molecular and Population Genetics and senior author of study, said, “Our study is the largest ever conducted of the genetics of bowel cancer, and sets out a detailed map of the disease that could lead us to new ways of treating or preventing it. Each cancer gene that has been discovered, or common genetic variant that we will continue to uncover, provides us with new insights into the underlying biology of the disease, and increases our ability to assess people for their risk.” The study was published on June 22, 2016, in the journal Nature Communications.

Related Links:
Institute of Cancer Research
Covaris
Illumina

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.